Cereno’s CEO: “CS014 adds potential for cardiovascular disease patients”
Cereno Scientific is a biotech company developing treatments for the number one killer in the world – cardiovascular disease. The company has been granted the approval from EMA to initiate a first-in-human phase I trial with candidate CS014 – a novel epigenetic HDAC inhibitor. Cereno’s CEO Sten R Sörensen stopped by the BioStock Studio to share more details about the news.
Watch the interview with Cereno‘s CEO Sten R Sörensen below:
